Oramed Pharmaceuticals (ORMP) Non Operating Income (2022 - 2026)

Oramed Pharmaceuticals has reported Non Operating Income for 5 years, with the latest figure at -$100000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 30.07% year-over-year to -$100000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (up 124.64% YoY), and the FY2025 full-year result was -$606000.0, up 73.49% from the prior year.
• Non Operating Income for Q1 2026 stood at -$100000.0, up from -$74.9 million in the prior quarter.
• The five-year high for Non Operating Income was $61.5 million in Q3 2025, with the low at -$74.9 million in Q4 2025.
• Historically, Non Operating Income has averaged $1.6 million across 5 years, with a median of $1.0 million in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income jumped 1731.08% — and 2024, when it sank 3644.83%.
• Oramed Pharmaceuticals' Non Operating Income stood at $1.0 million in 2022, then jumped by 1731.08% to $18.4 million in 2023, then slumped by 133.66% to -$6.2 million in 2024, then plunged by 1110.15% to -$74.9 million in 2025, then surged by 99.87% to -$100000.0 in 2026.
• The last three Non Operating Income figures came in at -$100000.0 (Q1 2026), -$74.9 million (Q4 2025), and $61.5 million (Q3 2025), per Business Quant data.